Key statistics
As of last trade Context Therapeutics Inc (CNTX:NAQ) traded at 1.84, -33.27% below its 52-week high of 2.75, set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.89 |
---|---|
High | 1.89 |
Low | 1.81 |
Bid | 1.82 |
Offer | 1.85 |
Previous close | 1.86 |
Average volume | 601.71k |
---|---|
Shares outstanding | 75.00m |
Free float | 73.91m |
P/E (TTM) | -- |
Market cap | 139.50m USD |
EPS (TTM) | -1.06 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 16:13 BST.
More ▼
Announcements
- BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
- Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
- Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
- Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
- Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
- Context Therapeutics Announces $100 Million Private Placement
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results
More ▼